If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

< Previous Abstract  |  Next Abstract >

Topical treatment of actinic keratoses with low-dose 5-fluorouracil in combination with salicylic acid – pilot study
Max Schlaak 1 , Jan C. Simon 1
  (1)Department of Dermatology, Venereology and Allergy, University of Leipzig, Germany
 Correspondence to
Dr. Max Schlaak
Department of Dermatology and
Venereology
Uniklinik Köln, University hospital
Cologne
Kerpener Str. 62
D-50924 Cologne, Germany
E-mail: max.schlaak@uk-koeln.de
Copyright Journal compilation © Blackwell Verlag GmbH, Berlin
KEYWORDS
actinic keratoses • 5-FU • salicylic acid • topical treatment

ABSTRACT

Background: Actinic keratoses (AK) are carcinomas in situ and can progress to invasive squamous cell carcinomas. Treatment of actinic keratoses can be achieved by physical ablation, chemotherapeutic agents, immunomodulators or photodynamic therapy.

Patients and Methods: We conducted a proof of concept study with 15 patients. Overall 66 actinic keratoses were treated with 5-FU (0.5 %) and salicylic acid (10 %) for 4 weeks (3 times per week).

Results: After 12 weeks complete response of 47 AK (77 %), partial response of 13 AK (21 %) and non-response of 1 AK (2 %) were achieved.

Conclusions: Treatment was well tolerated and efficient.


Submitted: 14.7.2009 | Accepted: 30.9.2009

DIGITAL OBJECT IDENTIFIER (DOI)
10.1111/j.1610-0387.2009.07293.x About DOI

Related Articles

  • Find other articles like this in Wiley InterScience
  • Find articles in Wiley InterScience written by any of the authors

Wiley InterScience is a member of CrossRef.

Cross Ref Member


Sign Up Now
Wiley Medical Twitter